ITF Therapeutics, headquartered in Concord, Mass., was established in January 2024 as the U.S. rare disease affiliate of Italfarmaco, a global pharmaceutical company based in Milan. With the launch of its first product in Duchenne muscular dystrophy, ITF Therapeutics pairs end-to-end commercial execution with deep engagement across the community – listening to advocates, researchers, clinicians, and families, to ensure their perspectives help shape innovative and potentially life-changing solutions. With expertise spanning regulatory, commercial operations, medical affairs, access, and community partnerships, ITF Therapeutics is powered by a growing multidisciplinary team focused on delivering proven therapies with urgency, ambition, and compassion.
MassBio Member Spotlight: ITF Therapeutics
Location: 575 Virginia Rd, Suite 201, Concord, MA 01742
Therapeutic area(s): Rare diseases, including Duchenne muscular dystrophy
Leadership: Matt Trudeau, President of ITF Therapeutics
Website: itftherapeutics.com
